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Background: Herpes zoster (HZ) or “shingles” is common in persons aged 50 years or over. HZ is characterised by a
painful dermatological rash which typically resolves in approximately one month. Persistent pain for months or
years after rash onset, however, is a common complication of HZ; referred to as post-herpetic neuralgia (PHN). Both
HZ and PHN have a significant impact on patients’ lives, with considerable implications for healthcare systems and
wider society. The aim of the present review is to provide comprehensive documentation and critical appraisal of
published data concerning the humanistic, economic and societal burden of HZ in Europe.
Methods: Systematic literature searches were conducted in Medline, EMBASE, PsycINFO, EconLit, HEED and CRD
databases. Searches were conducted in July 2014 and restricted to articles published in the past 20 years. Articles
were selected for full review by two independent researchers in accordance with predefined eligibility criteria.
Results: From a review of 1619 abstracts, 53 eligible articles, were identified which reported data concerning
healthcare resource use (n = 38), direct costs (n = 20), indirect costs (n = 16), total costs (n = 10) and impact on
health-related quality of life (HRQoL) (n = 21). Findings highlight that PHN is associated with greater impairments in
HRQoL and higher costs of management than HZ. For both HZ and PHN, pain severity is a significant predictor of
impact on individuals, healthcare systems and society. While the incidence of HZ and PHN increase with age, age
does not appear to be a key driver of overall costs for HZ and PHN. Specifically, while direct costs (e.g. GP, specialists,
medications, hospitalisations) tend to be higher for older patients, indirect costs (e.g. work time missed) are higher for
younger patients.
Conclusions: Available evidence highlights that HZ and PHN result in significant humanistic and economic burden for
patients, healthcare systems and wider societies. A tendency to focus upon healthcare resource use and the direct
costs of management at the expense of other impacts (e.g. informal caregivers and formal social care) may result in an
underestimation of the true burden of HZ and PHN.Background
Herpes zoster (HZ), also known as shingles, is caused by
the reactivation of the varicella zoster virus (VZV). Pri-
mary infection with VZV usually occurs during child-
hood, manifesting as chickenpox, after which the virus
lies dormant [1]. The great majority (95%) [2] of the
population hosts VZV and approximately one in four
persons will develop HZ in their lifetime through reactiva-
tion, leading to an estimated 1.7 million episodes in
Europe annually [3]. VZV reactivation is primarily related
to an age-related decline in VZV-specific immunity; it is* Correspondence: adam.gater@adelphivalues.com
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unless otherwise stated.well documented that the incidence of HZ increases with
age, with the majority of cases occurring in patients over
50 years of age [4].
HZ is characterized by a painful dermatomal rash,
which most commonly presents on the trunk and lum-
bar regions. HZ, however, may present along any nerve
including the ophthalmic division of the trigeminal nerve
where it can affect the eye. Herpes Zoster Ophthalmicus
(HZO) occurs in 10-20% of all HZ cases and in some
cases can lead to ocular complications [5].
The dermatological rash and pain associated with HZ
typically resolves within one month of presentation [4];
however, long-term complications can arise. Post-herpetic
neuralgia (PHN) is the most common and debilitating
complication of HZ, occurring in approximately 10-20%his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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85 years and over [9]. PHN is a neuropathic syndrome
manifesting as on-going pain along the nerves in the area
of the prior HZ rash and typically involves one or more of
the following: spontaneous aching or burning; paroxysmal
shooting pains; allodynia, and hyperalgesia [9,10]. There is
no consensus regarding the definition of PHN; however,
PHN is often defined as pain persisting for 90 days from
HZ rash onset [4,6,10,11]. While HZ is an acute experi-
ence that typically resolves within one month, in the ma-
jority of sufferers, PHN persists for at least 6 months with
some patients experiencing PHN for years [12-15]. As ex-
pected given the relationship to HZ, the incidence of PHN
increases markedly with age [16-18]. The incidence of
PHN is also linked to the severity of pain experienced dur-
ing the prior HZ episode (among other predictors such as
the severity of the dermatomal rash and prodromal symp-
toms) [19], with those patients experiencing the highest
levels of pain during HZ presentation being most at risk
of developing PHN [20].
As conditions primarily affecting older persons, many
patients with HZ and PHN may already experience sig-
nificant deficits in health status. Findings from a number
of articles indicate that the pain and resulting discomfort
associated with HZ and PHN can have a substantial
negative and widespread impact on patients’ health-
related quality of life (HRQoL) and patients’ ability to
engage in activities of daily living [7,20-25]. In addition
to the burden encountered by the individual with HZ,
the condition is also associated with considerable eco-
nomic burden. For example, considerable costs to health-
care systems [26-31] arise from the care provision for HZ
and PHN patients, including visits to primary care (gen-
eral practitioner) and outpatient secondary/tertiary care
(specialist pain clinics and ophthalmologists), inpatient
visits (hospitalisations) and prescription costs. Further-
more, HZ and PHN are also associated with significant in-
direct costs, primarily in terms of loss of productivity for
younger patients [7,21,23,24,28,32]. Finally, as conditions
occurring in retired and older patients, HZ and PHN can
also have significant consequences for the caregivers of
patients including partners, relatives, and friends of people
with the conditions [7]. Such details, however, may often
go unreported and are not often communicated in the re-
search literature.
Evidence for the efficacy of a VZV vaccine in the pre-
vention of HZ and PHN episodes and attenuation of the
severity of HZ and PHN episodes and associated impact
has been documented in recent years [11,33]. In order
to understand the value of preventative strategies, a
complete understanding of the impact of HZ and PHN
is required. While a significant body of literature has
sought to determine the impact of HZ and PHN on pa-
tients, healthcare systems and wider society within EUcountries, to date, no comprehensive review of these
studies has been conducted. The aim of this review,
therefore, is to provide a comprehensive and holistic
overview of the humanistic, economic and societal bur-
den of HZ and PHN in Europe as reported within the
published peer-reviewed literature.Methods
Published peer-reviewed articles were identified via sys-
tematic searches conducted in the following biomedical
and economic databases: EMBASE, Medline, PsycINFO,
EconLit, Health Economic Evaluations Database (HEED)
and the Centre for Reviews and Dissemination databases
at the University of York. Searches and reviews were
conducted in accordance with the Cochrane systematic
review guidelines [34]. A range of disease-related, eco-
nomic, societal and HRQoL-related keywords was uti-
lized to capture the humanistic, economic and societal
burden of HZ and PHN (see Table 1). Searches were
conducted in July 2014 and were restricted to articles
published in the last 20 years. Although data relating to
the EU was the primary focus of this review, no limits
regarding study country or article language were imple-
mented during the search stage (so to not exclude po-
tentially relevant articles). Instead, articles focused on
the EU were prioritized as part of the article selection
process.
In accordance with Cochrane review guidelines
[35], all abstracts were reviewed by two researchers
independently according to formal inclusion/exclu-
sion criteria (Table 2). For inclusion in the review,
abstracts were required present information specific
to adult patients in the EU and to contain informa-
tion pertaining to the key search terms (see Table 1).
In instances were aforementioned details were not
clear from the abstract, full text articles were obtained to
confirm whether the article should be included/excluded.
Real world data, observational studies, effectiveness
studies, qualitative studies, economic evaluations and
cost studies were all considered relevant for review.
The final list of abstracts and articles for full in-depth
review was agreed following consensus between the
authors.
Data extraction tables were developed to accurately
record information from the articles chosen for review.
Of importance was information related to the study
aims, design and outcomes of interest, sample character-
istics, country of study, resource use data, cost data (dir-
ect and indirect) and any patient-reported impacts of
HZ and PHN. All referenced costs are provided in Euros
and have been adjusted to the same price year (2015)
based on annual average rate of change (%) in the Har-
monised Index of Consumer Prices [36].
Table 1 Search terms
Databases searched Disease search terms Economic, humanistic and societal burden search
terms
• Medline “Herpes Zoster” OR “Shingles” OR “Post-herpetic
Neuralgia” OR “Post herpetic Neuralgia” OR
“Postherpetic Neuralgia” OR “PHN”
“Burden” OR “Humanistic” OR “quality of life” OR “QOL”
OR “HRQOL” OR “cost” OR “economic” OR “resource” OR
“society” OR “societal” OR “family” OR “relatives” OR
“Caregiver” OR “care$” OR “activities of daily living” OR
“ADLS” OR “daily activities” OR “cost of illness” OR




• Health Economic Evaluations
Database (HEED)
• Centre for Reviews and Dissemination
databases:
- Database of Abstracts of
Reviews of Effects (DARE),
- Health Technology Assessment
(HTA)
- NHS Economic Evaluation
Database (NHS EED)
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Search results
Figure 1 provides an overview of the article selection
process. A total of 1619 titles and abstracts were
reviewed against the inclusion/exclusion criteria, result-
ing in 78 EU based articles for full text review. A further
25 articles were excluded following full text review, leav-
ing a total of 53 studies to be included in this review.
Overview of selected articles
A summary of the 53 articles selected for inclusion in
the review (including study countries, population, data
presented) is provided in Table 3.
The references selected for review presented data from
14 European countries with the majority (n = 39, 73.6%)
of articles providing data from the ‘Big 5’ EU countries
(UK; Spain; France; Germany & Italy). Of the included
references, 39 reported data specifically attributed to HZ
patients and 35 reported data specifically attributed to
PHN patients. Data attributed to a combined HZ andTable 2 Study Inclusion/exclusion criteria
Inclusion criteria
Country setting Present data from a country in the EU or EU in general
Population Adults with HZ or PHN
Studies that contain information on key search terms
(inc. QoL, burden, productivity)
Study design Real world data, observational studies, effectiveness,
qualitative research and cost studies
Publication type For conference abstracts, exclusion if manuscript correspondiPHN population was included in 15 references. The ref-
erences eligible for inclusion in the study were all pub-
lished between 2000 and 2014.
Data presented in reviewed references was categorized
as follows: 1) Healthcare utilisation in terms of rates of
medical visits, hospitalisations and medication pre-
scribed, 2) Direct costs corresponding to the manage-
ment of HZ/PHN, 3) Indirect costs, 4) Total costs and
5) Health related quality of life and humanistic burden.
Of note, some references contained data pertaining to
multiple categories.
Healthcare utilisation
Information regarding healthcare resource was included
in 38 of the identified references (as summarized in
Table 3). Data indicated that HZ and PHN are associated
with considerable healthcare utilisation, with increased
resource use associated with increasing age and the pres-
ence of PHN. Data concerning healthcare utilisation was
presented in terms of rates of medical visits (includingExclusion criteria
Only present data from a non-EU country. No data
specific to the EU.
Children
Focus mainly on chicken pox
Immunodepressed patients only (e.g. HIV patients)
Studies that do NOT contain information on key search terms
Clinical trials of efficacy and safety of treatments
presenting QoL data as secondary endpoint only
Clinical trials of Zostavax
Focus mainly on epidemiological evidence (e.g. incidence, prevalence etc.)
ng to this abstract and presenting equivalent information is already published
Figure 1 Overview of study selection for review.
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ation of stay), use of medications and additional diagnos-
tic/laboratory procedures.
Medical visits
The majority of patients presenting with HZ will consult
their GP at least once [43,50]. Reflecting the chronic na-
ture of PHN, higher rates of medical visits (GP and spe-
cialist visits) have been reported in PHN patients
compared to HZ patients [14,21,27,29,50]. For example,
reports from a study in Italy indicated that patients over
the age of 50 with HZ made approximately 1.9 visits to
their GP. By contrast, the reported number of visits
among patients with PHN was 11.9 and 12.0 (PHN-
1 month and PHN 3-months definitions, respectively)
[29]. The proportion of patients referred to specialists
(74% PHN versus 18% HZ) and the number of specialist
visits per case (3.5 and 3.9 for PHN-1 month and PHN
3-months vs 0.2 for HZ) were also higher for PHN pa-
tients compared to HZ patients. More frequent specialist
visits have also been reported among patients with HZO
compared to those with HZ [21].
The average annual incidence of herpes zoster GP-
consultations has been reported to increase with age
from 32.8/10,000 among those aged <60 years, to 93.1
and 113.2/10,000 among those aged 60–64 years and
≥65 years respectively [64]. Similarly, the average num-
ber of specialist visits was also higher in patients over
the age of 50 compared to those over the age of 14 [27].
Hospitalisations
The rates of hospitalisations due to HZ and/or PHN re-
ported in the literature (generally derived from national
or insurance databases of hospital admissions) suggest
that increased rates of hospitalisation are also associated
with increasing age [55,71]. More frequent hospitalisa-
tions have also been observed among patients with PHN
when compared to patients with HZ across studies in
Italy [29], Belgium [40], France [55], Germany [73],
Spain [37,45,49,51,52,61]. and Portugal [59]. There arealso reports of a greater rate of hospitalisations among
female HZ patients compared to male HZ patients at
across all age groups [71].
The average length of inpatient stay for PHN (10.2 ±
8.6 days) has been reported to be higher than those asso-
ciated with HZ (7.8 ± 5.4 days) [29]. The average dur-
ation of stay in hospital among HZ patients also appears
to be influenced by age [47,74]. For example, analysis of
Hospital Episode Statistics (2002–2005) from England
indicates the average length of stay among HZ/PHN pa-
tients aged 60–64 is 9.3 days whereas those aged 85–90
is 22.3 days [74]. Comparisons between HZ and HZO
patients over 50 years of age also indicate longer hospital
stays in patients with HZO (9.8 vs 7.8 days) [38].
Medication use
It is reported that up to 100% of PHN patients and
83.2% of patients with HZ receive medication for their
condition across all ages [31]. Polypharmacy is common
among HZ patients with HZ patients reported to be tak-
ing at least 4 different medications on average and PHN
patients reported to be taking 5 medications [50]. This
could potentially have wider implications as polyphar-
macy is known to be a major cause of drug interactions
and issues with treatment adherence and safety [78].
The types of medication used has been reported to
vary depending on the population being considered (HZ
or PHN) [14,21,29,50]. Indeed, current treatment of HZ
aims to relieve pain, to limit the spread and duration of
the dermatomal lesions and (when started within 72 hours
of rash onset) to prevent or alleviate complications associ-
ated with HZ. By contrast, for PHN, the focus of medica-
tions is to alleviate pain [79,80].
The amount of available information regarding medi-
cation use in EU countries was somewhat limited; how-
ever available evidence from the literature suggests that,
despite the availability of European Guidelines for the
management of HZ [80,81], medication prescribing
practices (for the treatment of PHN in particular) are
not consistent across countries [14,21,25,29,44,50]. An
Table 3 Overview of included studies















Annemans et al. (2010) [26] Belgium ✓ X ✓ ✓ X ✓ ✓ ✓ ✓ X
Bayas et al. (2011) [37] Spain Catalonia X ✓ X X X ✓ ✓ X X X
Berrut, G. and C. Baptiste
(2013) [38]
France ✓ X X X X ✓ X X X X
Blein, C., et al. (2013) [39] France ✓ X X X X ✓ X X X X
Bilcke et al. (2012) [40] Belgium X ✓ X ✓ X ✓ ✓ ✓ X X
Bouhassira et al. (2012) [15] France ✓ ✓ X ✓ X X X X X ✓
Bresse, X., et al. (2013) [41] France ✓ X X ✓ X ✓ X X X X
Bricout, H., et al. (2013) [42] Italy ✓ X X X X X X ✓ X ✓
Bricout, H., et al. (2013) [42] Italy ✓ X X ✓ X ✓ X X X ✓
Brisson et al. (2003) [43] England & Wales X ✓ X X ✓ ✓ ✓ ✓ ✓ X
Castro-Lopes, J. M.,
et al. (2013) [44]
Portugal X X X X ✓ ✓ X X X ✓
Cebrian-Cuenca et al. (2011) [27] Spain, Valencia ✓ X ✓ ✓ X ✓ ✓ ✓ ✓ X
Chidiac et al. (2001) [21] France ✓ ✓ X X ✓ ✓ X X X ✓
De Juanes et al. (2011) [45] Spain Madrid X ✓ X X ✓ ✓ ✓ X X X
Di Legami et al. (2007) [46] Italy – Piemonte ✓ X X X ✓ ✓ ✓ X X X
Edmunds et al. (2001) [47] England and Wales X ✓ ✓ X X ✓ ✓ X X X
Franco, E., et al. (2013) [48] Italy ✓ X X ✓ X ✓ X X X ✓
Garcia-Doval et al. (2010) [49] Spain ✓ X X X ✓ ✓ X X X X
Gater, A., et al. (2014) [50] UK ✓ X X X X ✓ X X X ✓
Gauthier et al. (2009) [28] UK ✓ X ✓ ✓ X ✓ ✓ X X ✓
Gialloreti et al. (2010) [29] Italy ✓ X ✓ ✓ X ✓ ✓ ✓ ✓ X
Gil et al. (2004) [51] Spain ✓ X X X X ✓ ✓ X X X
Gil et al. (2009) [52] Spain ✓ X X X X ✓ ✓ X X X
Gil-Prieto et al. (2011) [53] Spain ✓ X X X X ✓ ✓ X X X
Gil-Prieto, R., et al. (2014) [54] Spain ✓ X X X X ✓ X X X X
Gonzalez et al. (2010) [55] France ✓ X X X X ✓ X X X X
Lionis et al. (2011) [56] Greece ✓ X ✓ X X X X X X ✓
Loncar, Z., et al. (2013) [57] Croatia ✓ X X X X ✓ X X X ✓





✓ ✓ X ✓ X X X ✓ X ✓
Mesquita, M. and F. Froes
(2013) [59]
Portugal ✓ X X X X ✓ X X X X
Mick et al. (2010) [30] France X ✓ X ✓ X ✓ ✓ ✓ ✓ X
Moore et al. (2010) [60] UK X ✓ ✓ ✓ X X X ✓ X X
Morant-Talamante, N., et al.
(2013) [61]
Spain ✓ X X X X ✓ X X X X
Mordarski et al. (2009) [62] Poland X X X X ✓ X X X X ✓
Nilsson, J., et al. (2013) [63] Sweden X ✓ X X X X X ✓ ✓ X
Pierik et al. (2012) [64] Holland/the
Netherlands
✓ X X X X ✓ X X X X
Rabaud, C., et al. (2013) [65] France ✓ X ✓ ✓ X ✓ X X X ✓
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Rehm et al. (2010) [66] 14 European countries
(countries not specified)
X X ✓ X X X X X X ✓
Schiffner-Rohe et al. (2011) [67] Germany ✓ X ✓ X X ✓ ✓ X ✓ X
Scott et al. (2003) [68] UK ✓ X X ✓ X X X X X ✓
Scott et al. (2006) [7] UK X ✓ X ✓ X X X ✓ ✓ ✓
Serpell, M., et al. (2014) [14] UK X X X ✓ X ✓ X X X ✓
Sicras-Mainar et al. (2012) [69] Spain ✓ ✓ X X ✓ ✓ ✓ ✓ ✓ X
Souliotis, K., et al. (2013) [70] Greece X ✓ X X X X ✓ ✓ X X
Studahl, M., et al. (2013) [71] Sweden ✓ X X X X ✓ X X X X
Szucs (2011) [72] Switzerland ✓ X X ✓ ✓ X ✓ ✓ ✓ X
Ultsch et al. (2011) [73] Germany ✓ X X ✓ X ✓ X X X X
Ultsch et al. (2012) [31] Germany ✓ X X ✓ X ✓ ✓ ✓ ✓ X
Van Hoek et al. (2009) [74] England and Wales ✓ X X ✓ X ✓ ✓ X X X
Van Seventer et al. (2006) [25] France, Germany, Italy,
Netherlands, Spain, UK
X X X ✓ X ✓ X X X ✓
Volpi et al. (2007) [75] Italy ✓ X X X X X X X X ✓
Volpi et al. (2008) [76] Italy ✓ ✓ X ✓ ✓ X X X X ✓
Weinke et al. (2010) [77] Germany ✓ X X ✓ X X X ✓ X ✓
✓ and x indicate the presence/absence of evidence, respectively.
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conducted in France, Germany, Italy, Netherlands,
Spain and the UK (n = 84), for example, reported that
neuropathic pain medications (89%), analgesics (64%)
and anticonvulsants (52%) were most commonly pre-
scribed for the treatment of PHN [25]. However, a
study conducted in the UK reported that antidepres-
sants were most commonly prescribed for PHN
followed by level 1 and 2 analgesics (59.2%, 55.3% and
50% respectively) [14]. Similarly, studies in Italy and
Portugal have reported that anticonvulsants to be the
most commonly prescribed treatment for PHN, followed
by opioid analgesics [29,44]. Where reported, medication
usage for the treatment of HZ was consistent across stud-
ies; with antivirals (typically taken for 7 days) the most
commonly prescribed treatment [14,21,29,42,50,71].
Of note, despite the widespread use of pharmacological
therapies for the management of HZ and PHN, reports
from patients indicate dissatisfaction with treatments, par-
ticularly in regards to perceived efficacy [14,50].
Diagnostic/laboratory procedures
Details of additional investigations among patients with
HZ and PHN were reported from studies in France,
Italy, Spain and the UK [14,21,27,29,50]. Additional in-
vestigations reported included blood and urine tests,
assessments of inflammation (e.g. erythrocyte sedimen-
tation rate, C-reactive protein level), ophthalmological/
ontological examinations, radiology, X-ray, electrocar-
diograms and ultrasound.Further diagnostic or laboratory examinations were
reported in 28.0% of incident cases of HZ among an
Italian sample of immunocompetent individuals, with
the mean number of procedures and examinations re-
ported to be 2.6 per case [29]. By comparison, rates of
additional investigations reported in France, Spain and
the UK were lower [14,21,27,50], with evidence suggest-
ing that rates of additional investigations were higher in
those with PHN (10–12.5% compared to HZ (4.4-9%)
[14,21,50]. Additional investigations are also more likely
among those patients with HZO compared to HZ [21].
Direct costs of management
Direct costs of the management of HZ and PHN patients
were reported in 20 studies. The reviewed articles presented
data from Spain [27,37,45,51-53,69], the UK [7,28,43,47,74],
France [30], Italy [29,46], Germany [31,67], Belgium
[26,40], Greece [70] and Switzerland [72]. Outpatient
costs (including medical visits, diagnostic tests and
medications), hospitalization and inpatient costs were
identified in the literature as key contributors to the
overall cost burden of HZ and PHN.
Outpatient costs
Studies in Belgium [26], Germany [31,67], Italy [29] and
the UK [28] have consistently reported higher outpatient
management costs (including medical visits, diagnostic
tests and medications) among patients who go on to de-
velop PHN. For example, mean direct costs of outpatient
management have been reported as €107.98 per HZ
Gater et al. BMC Public Health  (2015) 15:193 Page 7 of 15episode and €406.04 and €485.51 per PHN episode (1-
and 3-month definition respectively) [28]a. In addition,
costs for outpatient management of HZ and PHN have
been reported to increase markedly with pain severity
[26,28]. For example, outpatient costs among HZ patients
ranging from €85.89 (no pain) to €178.32 (severe pain) per
case have been reported in the UK. Reported differences
are more pronounced among PHN patients with costs per
case ranging from €237.90/284.80 (PHN1/PHN3) among
patients with mild pain to €741.91/878.88 (PHN1/PHN3)
among patients with severe pain [28]a. Key differences in
the attribution of outpatient costs for HZ and PHN have
been reported for Italy; for patients that did not develop
PHN, the majority of the cost of management has been re-
ported to be due to the cost of medication (83%) whereas
for patients that develop PHN a greater proportion of cost
was attributed to diagnostic and investigative procedures
[29]. Other studies, however, indicate costs of diagnostic
procedures to be the smallest contributor to outpatient
costs among patients with HZ and PHN (PHN-1 and
PHN-3) [27].
While the average cost of outpatient management per
case is higher for patients with PHN than for patients
with HZ, when considering overall burden of disease at
a country level, the overall cost of disease is higher for
HZ. This is primarily a result of the higher incidence
rates of HZ. These differences were highlighted by one
study which investigated the annual cost of HZ and
PHN to healthcare providers located in England and
Wales [47]. Based on an estimated 260,995 episodes of
HZ occurring annually, with 14% of cases developing
PHN, an estimated €76.39 milliona is spent on the man-
agement of HZ (including PHN). Of this, €52.32 million
was attributable to HZ (€22.47 m due to hospitalisation,
€19.26 m due to prescription medications and €9.63 m
due to GP consultations) and €24.07 million to PHN1
(cost breakdown not provided). Similar findings are re-
ported in Germany where statutory health insuranceTable 4 Mean cost per hospitalised case of HZ/PHN, by count
Country HZ/PHN HZ (with
Belgium [40] - €5,982 (€
(all ages)
France [41] - €2,774.28
Germany [31] - €4,189.74
€3,282.64
Italy [29] - €3,188.16
Spain [37,45,52,53] €3,366.4 -4,505.6 €5,019.84
(all ages) €4,495.68
€4,210.92
€4,062.24bills have been estimated at €115.5 m; €93.5 m attrib-
uted to HZ treatment and €22 m attributed to treatment
of PHN [31].
Hospitalisation and inpatient costs
Hospitalisation costs contribute significantly to the over-
all direct cost of managing HZ and PHN. Rates of hospi-
talisation and duration of stay were found to be higher
for PHN than for HZ, and to increase with increasing
age, translating into higher inpatient costs for patients
that develop PHN (Table 4) [18,24,33,70]. Note that data
on hospitalisations and inpatient costs was primarily ex-
tracted from a range of national and insurance databases
in each country. No studies identified provided a break-
down of the cost elements that are included in a ‘hos-
pital stay’.
Indirect costs
Indirect costs considered in the EU literature were
mainly related to costs associated with sick leave (absen-
teeism). Seventeen articles reported data on sick leave
due to HZ and PHN and the costs that this incurs
[7,26,27,29-31,40,42,58,60,63,69,70,72,73,77,82]. Absentee-
ism due to HZ and PHN is a significant cost driver, with
increased costs found to be associated with the presence
of PHN [29,31,72] and increased levels of pain experi-
enced [26,72]. Up to 65% of employed patients report
work absence due to their disease [77].
Costs associated with absenteeism varied across EU
countries. In France, these costs accounted for up to
30% of the costs of management of HZ from the societal
perspective and up to 10% of the costs of management
for PHN in patients aged 50 years and over [30]. In
Germany, the mean annual cost of sick leave due to HZ
was €1,504 per patient (increasing to €1,826 for patients
over the age of 50), with patients missing an average of
12.5 days from work. The costs associated with PHN





(all ages) €4,112.03 (all ages)
± €1,614.99 (50+years) €3,451.38 ± €3,248.43 (50+years)
(aged 40–49) €5,108.04 (aged 50–59)
– 5,139.54 (aged 50–59) €4,732.56 (aged 60–69)
– 4,782.96 (aged 60–69) €4,478.04 (70+)
– 4,556.16 (aged 70+)
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from work [31]. The average costs associated with ab-
senteeism were found to be lower in Italy and
Switzerland than those reported for Germany [29,72].
Average costs for patients over the age of 50 in Italy
were €684 per case of HZ and €978 per case of PHN
[29]. In Switzerland, reported costs of sick leave per case
for patients with varying levels of pain were as follows:
mild pain (HZ €335; PHN 381), moderate pain (HZ €421;
PHN €1,018), severe pain (HZ €1,837; PHN €2,443)b [72].
In Spain, the findings from an observational study [27]
of 130 HZ patients aged 19–45 (median age of 63.5 yrs)
who were observed for 1 year suggest that an average of
4.3 hours of work were missed per patient at a cost of
€52.98. This study also found that a total of 6 work
hours were lost by carers across the study sample of 130,
resulting in a total loss of €86.31. The cost and time im-
plications of time taken off work by carers were also
considered in two further studies that were conducted in
Belgium and the UK respectively. The study conducted
in Belgium found that 14/184 patients reported that
someone else could not go to work due to their illness
for between 0.5-10days, resulting in an average loss of
€52 per case due to carer absenteeism [40]. For the
study conducted in the UK, among 70 HZ patients, a
total of 52 work days were lost by their carers [7]. How-
ever as the majority of the reviewed studies usually do
not report the cost burden associated with time lost by





Belgium [26] Aged ≥50 €118 (no pain)
€1,150.50 (severe pain)
France [30] Aged ≥50 €419.87 (271–586)
Germany [31] Aged ≥50 €388.30 (354–425)
Germany [67] Aged ≥50 €729.57
Italy [29] Aged ≥50 €888.06
Spain [27] Aged >14 Overall: €446.04 (SD 50
50-59: €282.06 (SD 273.
60-69:€510.52 (SD 512.7
>70: €422.91 (SD 388.66
Spain [69] Aged >30 €460.95
Sweden [63] All ages
Switzerland [72] Aged ≥50 €394.46 (no pain)
€1,835.57 (severe pain)
UK [7] Not specified €793.60 (31–6,394)
(all ages) Aged +65: €788.48
*PHN defined as pain persisting for one month following resolution of HZ rash.
^PHN defined as pain persisting for three months following resolution of HZ rash.Total costs of management
A total of 10 studies reported the total cost per case of
HZ and/or PHN in EU countries, taking into account
both direct costs (including medical visits, medications
and hospitalisations) and indirect costs (including time
missed from work). Table 5 presents the average cost
per case in each country based on the data that was de-
tailed in the reviewed literature. Overall, higher costs
were consistently associated with the presence of PHN
and increased levels of pain. Of note, whilst HZ and
PHN are associated with higher costs to healthcare pro-
viders in elderly populations, costs to society in terms of
time missed for work tends to be lower, so the total
costs overall are similar across age groups [60].
The total annual cost (direct and indirect costs) of HZ
and PHN on a country level basis was only available for
the UK [43], France [30], Germany [31], Italy [29] and
Sweden [63]. Two studies presented data separately for
the cost of HZ and PHN and patients over the age of 50
[29,31]. Further details are provided in Figure 2.
Humanistic burden and impact on quality of life
A total of 21 EU studies [7,14,15,21,25,28,42,44,48,50,56-58,
62,65,66,68,75-77] reported data on the humanistic burden
associated with HZ and PHN, with the significant negative
impact of HZ and PHN on patients’ HRQOL consistently
reported. Of note, pain experienced due to the disease was
found to interfere with many aspects of patient’s daily life.
Greater interference was associated with increased levels ofPHN1* PHN3^
€156.94 (mild pain) €329.22 (mild pain)










€902.88 (HZ and PHN)
- €381.15 (no pain)
€2,442.99 (severe pain)
- -
Figure 2 Estimated total cost burden associated with HZ and PHN considering outpatient, hospitalisation and indirect costs.
Table 6 Level of pain interference across seven health
state domains as assessed by the ZBPI (or similar
instrument)
Health state domains HZ (mean scores) PHN (mean scores)
General activity 3.8-4.4 3.1-5.7
Mood 3.4-4.5 3.4-5.9
Walking ability 1.7-4.0 1.7-5.8
Normal work 3.3-4.4 2.9-6.1
Social relations 2.1-3.5 2.1-5.4
Sleep 4.5-4.9 6.3-6.5
Enjoyment of life 3.6-4.0 3.8-5.2
Data from Bouhassira 2012 [15], Gater 2014 [50], Lukas 2012 [58], Serpell 2014
[14], Weinke 2010 [77].
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a greater impact on most domains of HRQoL [14,50,58,77].
Patients also reported consequences for their family and
social circle when suffering from HZ or PHN [58,77,84].
Pain and interference with daily activities
Reports within the reviewed literature indicate that pa-
tients with HZ and PHN experience moderate-severe
pain. Ratings of average and worst pain reported in the
literature are higher among PHN patients compared to
HZ patients [14,41,50,58,77].
A number of the reviewed articles provided data from
the Zoster Brief Pain Inventory (ZBPI) and the Modified
Brief Pain Short Form (mBPI-SF)c – derivative measures
of the Brief Pain Inventory (BPI) which require patients
to rate the level of interference they experience on a
scale of 0–10 (‘does not interfere’ – ‘completely inter-
feres’), across seven health status domain; general activ-
ity, mood, walking ability, normal work, social relations,
sleep and enjoyment of life. Table 6 presents the mean
scores for patients with HZ and PHN from five studies.
In general, reports of pain interference on all seven
health status domains were greater among patients experi-
encing PHN compared to patients with HZ [14,50,58,77].
HZ and PHN patients reported sleep to be the aspect of
their daily lives most affected by pain (4.5-4.9 and 6.3-6.5
mean scores respectively), while walking ability was the
least affected in HZ patients (1.7-4.0 mean score) and en-
joyment of life was least affected in PHN patients (3.8-5.2mean score) [14,15,50,58,77]. Increased levels of pain are
reported to be associated with increased levels of interfer-
ence [25,83]. Levels of pain interference, however, do not
appear to be associated with age. Lukas et al. [58] pre-
sented pain interference data separately for six European
countries included in the study. While differences in the
level of interference observed varied from country to
country, the domains of health status most affected was
largely consistent.
Impact on general health-related quality of life
A number of studies have included generic HRQoL mea-
sures such as the SF-12 [15,83], SF-36 [14,21,50], EQ-5D
[7,14,25,50] and Short Italian Questionnaire (SIQ) [75,76]
Gater et al. BMC Public Health  (2015) 15:193 Page 10 of 15to assess HRQoL in HZ and PHN patients. Generally,
HRQoL has found to be inversely associated with levels of
reported pain [14,25,50,83] and the poorest HRQoL has
been observed for patients with PHN [14,21,50].
Consideration of HRQoL scores from normative popu-
lations indicates an inverse relationship between age and
HRQoL. As a condition mainly inflicting the elderly,
therefore, HRQoL is already considerably compromised
in HZ and PHN patients. Nonetheless, recent research
indicates that both HZ and PHN patients demonstrate
statistically significant and clinically relevant deficits in
HRQoL when scores for validated measures of HRQoL
(e.g. SF-36 and EQ-5D) among these populations are
compared to those from aged-matched normative sam-
ples (Figures 3 and 4) [14,50].
Impact on mood and mental well-being
Data presented across studies demonstrates that pa-
tients experience a negative impact on their mood and
mental well-being, with patients reporting stress, anx-
iety and depressive symptoms [14,15,50,56,58,76,77].
Across studies, a range of instruments have been used
to assess the impact of HZ and PHN on mood, includ-
ing the Hospital Anxiety and Depression scale (HADS)
[7,15], 10,47 Short Italian Questionnaire (SIQ) [75,76],
the Short Anxiety Screening Test (SAST) [56] and be-
spoke questions [58,77]. Up to 29% of patients with HZFigure 3 Comparison of SF-36 domain and component scores for HZ p
**p>0.01; ***p <0.001. † = clinically meaningful PF=Physical functioning, R-P=Ro
functioning, R-E=Role-emotional, MH=Mental health, PCS=Physical component s
initial presentation of HZ to healthcare professional and then again 7-14 daysreported feelings of moderate anxiety or depression, ris-
ing to 43% in patients with PHN. Further, a larger per-
centage of PHN patients reported extreme anxiety or
depression (11% vs. 5%) [58,77], evidencing that mood
and mental well-being issues are greater for PHN pa-
tients. The majority of patients reported experiencing
stress some of the time (up to 78% for HZ and 91% for
PHN) or most of the time (up to 19% HZ and 41%
PHN) [58,77].
Impact on family and social relations
Up to 50% of patients with HZ and 81% of patients
with PHN reported consequences for their family
members and social circle [58,77]. Despite the high
proportion of patients reporting impacts on their social
and family lives, only three studies assessed this issue
beyond comparing scores on social dimensions of in-
struments such as the ZBPI or SF-36 [58,77,84]. In one
study in particular, one fifth of the respondents felt iso-
lated from their family and friends while suffering from
HZ or PHN, with 19% and 27% of patients respectively
reporting reduced communication during their illness
[58]. Of note, impacts were not limited to the patient
themselves, with findings from a qualitative focus
group of patient’s relatives demonstrating that relatives
were worried and stressed by the impact of HZ on the
patients [84].atients compared to age-matched norms [50]. No *s p≥0.05, *p<0.05;
le-physical, BP=Bodily pain, GH=General health, V=Vitality, SF=Social
ummary, MCS=Mental component summary. Note: Data collected on
later (follow-up).
Figure 4 Comparison of SF-36 domain and component scores for PHN patients compared to age-matched norms [14]. No *s p≥0.05,
*p<0.05; **p<0.01; ***p <0.001. † = clinically meaningful PF=Physical functioning, R-P=Role-physical, BP=Bodily pain, GH=General health, V=Vitality, SF=Social
functioning, R-E=Role-emotional, MH=Mental health, PCS=Physical component summary, MCS=Mental component summary.
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The aim of this article was to provide a holistic overview
of the published literature concerning the humanistic,
economic and societal burden of HZ and PHN in Europe.
The reviewed evidence highlights the significant burden of
HZ and PHN for patients, healthcare systems and wider
society. A number of key findings are noted. Firstly, the
direct costs of managing HZ represent a significant pro-
portion of the total costs associated with the disease, with
higher costs associated with the presence of PHN and with
greater pain severity. Secondly, absenteeism was identified
as a significant cost driver (albeit in a small number of
studies), with up to 65% of employed patients reporting
work absence due to their disease. Lastly, research sug-
gests that age, pain severity and the presence of PHN are
the key drivers of burden to patients, healthcare systems
and society.
In Europe the percentage of people aged 65 years or
over is projected to increase from 17.1% (84.6million) in
2008 to 30.0% (151.5 million) in 2060 [85]. This demo-
graphic shift is likely to have a profound influence on
the incidence of HZ and PHN and may contribute to in-
creased concern among European healthcare authorities;
particularly if economic crisis and healthcare budget
constrains persist in the long term. Findings from this
review indicate that the direct costs of HZ and PHN
management are greater for older patients. In addition,
older adults typically have lower HRQoL than younger
adults (deficits which are more pronounced with the
presence of HZ and PHN) and may be less able to
complete activities of daily living and self-care unassisted.The potential implications of an aging population to wider
society, therefore, are wide reaching.Limitations of the current literature and potential gaps
that provide opportunities for future research
A number of limitations concerning the currently avail-
able body of evidence were identified.Inconsistencies in data
There is currently no consensus regarding the definition
of PHN and a lack of consistency in the definition of
PHN employed in studies was evident throughout the
review. This presents a number of challenges when
attempting to accurately understand the burden of HZ
and PHN. For example, it has been demonstrated that
the prevalence of PHN varies dramatically depending on
the point at which HZ-related pain becomes classified as
PHN (PHN1 or PHN3) [86]. Accurately attributing costs
to HZ and PHN and determining the overall cost burden
of the conditions, therefore, is difficult. Similarly, cost
per case may vary dramatically depending on the definition
employed. For this reason, PHN definitions employed in
the referenced studies have been highlighted throughout
this review and should be considered when interpreting
the findings from individual studies.
Furthermore, there is a lack of consistency in the use
of International Classification of Diseases (ICD) codes
used to identify PHN patients in clinical practice. As a
result, there may be a significant proportion of PHN pa-
tients who have not been considered in these studies;
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estimates regarding the burden of PHN.
A lack of consistency in the ways in which data had
been collected provides further difficulties in interpret-
ing and comparing the available data across studies, with
databases, patient records and patient surveys all uti-
lized. For example, rates of resource use were derived
from a range of sources including: analysis of patient re-
cords or an observed sample, patient responses to sur-
veys and national and insurance databases, with each of
these methods having their own limitations. The use of
databases is a valuable way of gathering data at a na-
tional level, however it assumes information is recorded
consistently and accurately across databases and that the
database has adequate and representative population
coverage. Analysis of patient records assumes informa-
tion is accurately recorded by GPs, who have a myriad
of demands on their time, and analysis of patient’s re-
sponses assumes accuracy in their recall. Of note, the
incidence of hospitalisations were largely based on rates
derived from databases in different countries, or rates
recorded in observed samples, thus inaccuracies may
occur when these data are extrapolated to the country
population. Variation in reports of healthcare resource
use, indirect costs and humanistic burden are also likely
to have resulted from inconsistency in the time frame
that different studies considered relevant.
With respect to the literature on economic burden, it
is understood that costs are likely to vary between coun-
tries in terms of the cost of medical resources, medical
visits and prescribed medications. Currently these differ-
ences are not reflected in the published literature and in
some cases, the cost of treating a case of HZ or PHN
were calculated inconsistently, with some studies pre-
senting the cost per treated case while others presented
the average across all patients. As such there was a wide
variation between studies. Only one study provided costs
(per treated case) for the different types of medications
used to treat HZ or PHN [46]. Similarly, no studies
provided breakdown or clarification of cost elements
included in a ‘hospital stay’. Great caution, therefore,
should be taken in comparing and interpreting the
available data. Furthermore this highlights an unmet
need for data that clearly distinguishes between HZ
and PHN and also for ‘per treated case’ data for a wide
range of EU countries.
A further notable limitation was that data were not
available for all EU countries. Despite comprehensive
database searches, in which no restrictions on country of
interest or language of publication were implemented,
cost burden data for the majority of Eastern European
countries was not identified. The majority of studies, in-
stead, focus primarily on the UK, Spain, France, Italy,
Belgium and Germany.Gaps in evidence
A number of evidence gaps were identified, some of
which provide opportunities for future research. A key
gap identified in the available evidence pool relates to
how indirect costs are assessed. While a number of EU
studies presented data on the time missed from work
and associated costs, data on productivity while at work
and associated costs is lacking. Studies in the US and
Canada, however, report that presenteeism could ac-
count for up to 75% of the cost burden associated with
work loss [87] and that an average of 46 hours were lost
(per employed patient) due to presenteeism [88].
In Europe, decisions regarding access and reimburse-
ment of medical interventions are predominately driven
by considerations of cost-effectiveness. Consideration of
the impact of conditions as reported by patients them-
selves, however, provides important information regarding
unmet need and the efficacy of medical interventions. A
number of studies assessing aspects of humanistic burden
associated with HZ and PHN were identified. However,
there are number of notable limitations. Firstly, the impact
of HZ and PHN was generally assessed using disease spe-
cific questionnaires (such as the ZBPI) or ‘bespoke’ ques-
tions which have not been tested or validated. There was
only limited use of generic HRQoL instruments in the EU
studies conducted to date. However, data from such in-
struments are valuable for quantifying burden with refer-
ence to the normative population and patients with other
diseases – data that is important for contextualizing the
relative burden associated with HZ and PHN. The avail-
able evidence does not typically look beyond the pain
which accompanies or persists beyond the rash and the
omission of other factors that can impact on patients’
quality of life (e.g. fatigue, stomach upsets, allodynia, and
numbness). This should be addressed, preferably through
a combination of quantitative and qualitative research, the
latter of which was notably lacking in the literature.
Finally, the lack of literature relating to the wider soci-
etal burden potentially caused by HZ and PHN (particu-
larly with respect to the impact on caregivers and the
broader implications of HZ and PHN on provision of
formal and informal social care) may be considered a
critical gap. To date burden among informal caregivers
has rarely been considered, and only in terms of time
lost from work. Significantly, this omits the potential im-
pacts of providing informal care to patients that may not
have resulted in time lost from work (e.g. negative im-
pact on the health and well-being of caregivers). Further-
more, consideration of healthcare resource use and the
economic burden of HZ and PHN has typically focussed
on impacts within the healthcare system; the broader
implications of HZ and PHN are rarely appreciated. For
example, the functional deficits observed among HZ and
PHN patients that may lead to a loss of autonomy and
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timated. Beyond some evidence of direct and indirect
costs related to the disease, the potential impact of HZ
and PHN on the social care system remains unknown.
Conclusions
This literature review highlights the burden faced by pa-
tients, healthcare systems and society due to HZ and
PHN in Europe. While the incidence of HZ and PHN in-
creases with age, the total cost per case of HZ and PHN
management is not necessarily age-dependent. Pain se-
verity was associated with increased costs for both HZ
and PHN, and, as a chronic condition, costs were higher
for patients experiencing PHN. No study fully addressed
the humanistic and economic burden of HZ and PHN
to patients, their families and society as a whole. Based
on the reviewed evidence and an assessment of the gaps
in the evidence base, it is likely that the true burden of
HZ and PHN is underestimated in the Europe. Further
research is required to build a holistic understanding of
the impact of HZ and PHN to patients, healthcare sys-
tems and society.
Endnotes
a*Costs originally reported in 2006 GBP sterling (£),
converted to euros (€) using the following conversion
rate £1 = €1.18.
b*Costs originally reported in 2006 Swiss francs (CHF),
converted to euros (€) using the following conversion
rate 1CHF = €0.81.
cAlthough 2 studies do not report a specific instru-
ment, items reported appear to be derived from the
ZBPI (38, 55).
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